Who we are

Company Profile

Versantis is a global clinical-stage company pursuing a highly-differentiated approach to the treatment of orphan liver diseases and ultra-rare pediatric urea cycle disorders. 

Our ambitious pipeline is fueled by strong science and covers a wide range of rare and non-rare indications from chronic to acute conditions. We believe our novel approaches may revolutionize current standard of care to improve patients’ lives and potentially relieve health care systems from the economic burden of liver diseases.

The Team
Mark J. Fitzpatrick CEO and Board Member
Vincent Forster PhD CSO, Co-Founder, and Board Member
Meriam Kabbaj PhD COO, Co-Founder, and Board Member
Prof. Katharina Staufer MD CMO
Pamela Williamson MBA Acting VP Regulatory Affairs
Lise-Marie Füeg Head of CMC
Rini Petrausch PhD Head of Clinical Operations
Kalman Wijaya MBA Head Market Access
Rekha Johnson PhD Compliance Lead
Leo Hofmann R&D Project Leader
The Board of Directors
Peter Nicklin Chairman
Mark J. Fitzpatrick CEO and Board Member
Vincent Forster PhD CSO, Co-Founder, and Board Member
Meriam Kabbaj PhD COO, Co-Founder, and Board Member
Michael Sidler PhD Board Member
Robert Schier PhD Board Member
Christopher Seaton MBA Board Member
Lluís Pareras MD PhD (Board Observer)
Regulatory Advisors
Pamela Williamson MBA Acting VP Regulatory Affairs
Scientific Advisory Board
Prof. Jean-Christophe Leroux PhD Member of the Scientific Advisory Board
Our Investors
Awards and Recognition